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Abstract 
Breast cancer is a genetically complex disease that affects over 230,000 people in the U.S. every 
year. Estrogen signaling has been shown to play a large role in the development and progression 
of breast tumors that express the estrogen receptor (ER). Thus, aromatase inhibitors (AIs), which 
prevent the synthesis of estrogen, have been increasingly valuable for the management of ER+ 
breast cancer. A frequent obstacle, however, is acquired resistance to AIs, characterized by 
heightened growth factor signaling and estrogen-independent growth. Another aspect of acquired 
AI resistance that is now being examined is the role of microRNA (miRNA). miRNAs are 18-22 
base pair RNA molecules whose primary role is to inhibit expression of mRNA targets by 
inhibition of translation or by degradation of the mRNA. Here, we have conducted next-
generation sequencing of the miRNAs from three breast cancer cell lines – one ER+ line that is 
estrogen-dependent (MCF-7), and two ER+ long-term estrogen deprived (LTED) models of 
estrogen-independent growth (MCF-7:5C and MCF-7:2A). We found that in the LTED MCF-
7:5C and MCF-7:2A cells there were 338 and 241 miRNAs differentially expressed, 
respectively, compared to the MCF-7 cells. We also saw unique miRNA clusters expressed in 
each LTED cell line – on chromosome 14q32 in the MCF-7:5C cells and on chromosome 13q31 
in the MCF-7:2A cells. Our initial in vitro work focused on the functional significance of miR-
181a (overexpressed in both LTED cells). This work has shown that miR-181a is regulated by 
estrogen/ER signaling, that loss of miR-181a in the LTED MCF-7:5C cells has a significant 
effect on proliferation, and that overexpression of miR-181a increases the ability of MCF-7 cells 
to grow in an estrogen-deprived environment. Since our LTED MCF-7:5C cells are more 
sensitive to DNA damage and overexpress miR-181a, which targets BRCA1, it was surprising 
that these cells were not more sensitive to the PARP inhibitor olaparib, which may be explained 
by high basal expression of BRCA1. Overall, it is clear that the miRNA profile of estrogen-
dependent breast cancer cells is unique from the estrogen-independent LTED cells, and miR-
181a may have a functional role in the estrogen-independent phenotype of our LTED MCF-7:5C 
cells.  
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Introduction 
Breast cancer and the role of estrogen 
Breast cancer is the second leading cause of cancer death and one in eight women will get 
breast cancer in her lifetime [1]. About 70% of all breast cancers express estrogen receptor alpha 
(ERα) and belong to the molecular subtypes luminal A or B [1, 2].  While the exact etiology of 
breast cancer is not known, there is strong evidence that estrogen plays a critical role in the 
development and progression of the disease. The earliest correlations of estrogen and breast 
cancer were reported in the late 19th century. In an 1896 issue of Lancet, Dr. George Beatson 
reported about a patient of his who presented with inoperable recurrent breast cancer, and 
because of his studies of lactation in sheep he predicted that removal of the ovaries would cause 
the breast cancer to regress [3]. Indeed, eight months after the oophorectomy, the woman showed 
no sign of the cancer [3]. In a similar report in 1900, Dr. Stanley Boyd concluded that 
oophorectomy can be used as adjuvant therapy for breast cancer patients who are older than 40 
years of age but have not yet entered menopause [4]. These results are supported by a study 
showing that breast cancer xenografts in athymic, oophorectomized mice depend on the presence 
of estradiol, and another study that correlates breast cancer risk with levels of circulating 
estrogens, such as estradiol [5, 6]. 
Estrogen mediates its biological effects by binding to estrogen receptors ERα and ERβ, 
which are members of the nuclear receptor superfamily of ligand-inducible transcription factors 
[7, 8]. ERα is encoded by ESR1, a 473 kb gene located on chromosome 6, and has six functional 
domains, A-F, which include both ligand-binding and DNA-binding domains, as described by 
Kumar and co-workers (Fig. 1) [9]. There are two transactivation domains, AF-1 and AF-2, on 
ERα, which are binding sites for other transcription factors and coregulators of ERα. It is also 
important to note that there are multiple sites of phosphorylation on ERα (Fig. 1). For instance, 
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Ser118 phosphorylation by a MAPK (mitogen-activated protein kinase) or Ser167 
phosphorylation by Akt (protein kinase B) can lead to activation of ERα, and when the 
expression of these kinases is aberrantly upregulated it can lead to ligand-independent 
phosphorylation and action of ERα [10, 11]. 
In the classic model of estrogen signaling, estrogen diffuses across the cell membrane and 
binds ERα. The receptor dimerizes and translocates to the nucleus where it binds estrogen 
response elements (EREs) in the DNA, stimulating transcription of target genes involved in cell 
proliferation and survival (Fig. 1) [12]. Both ligand-bound and ligand-free ERα has been found 
bound to the promoter of ERα target genes, further confirming the existence of ligand-
Figure 1. Functional domains and action of estrogen receptor alpha. The estrogen receptor alpha (ERα) 
protein has 6 functional domains (A-F) which allow it to perform its function as a transcription factor in the 
nucleus. This transcriptional regulation performed by ERα normally occurs when ERα is bound to its ligand – 
estrogen (green circles) – but can also occur in a ligand-independent manner. Both ligand-dependent and ligand-
independent functions of ERα require phosphorylation and dimerization of the receptor and translocation to the 
nucleus where it performs its function as a transcriptional regulator of genes with promoter motifs such as 
estrogen receptor elements (ERE), or binding sites for the transcription factors Ap-1 and Sp-1. Many of the ERα 
target genes play a role in cell proliferation and survival. 
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independent ERα action [13]. ERα is also able to bind other transcription factors, such as Ap-1 
and Sp-1, independent of EREs, where it may recruit co-activators to stimulate transcription of 
additional growth and survival genes [14]. Much of the molecular signaling mediated by ERα 
involves the MAPK and PI3K (phosphoinositide 3-kinase) pathways, the primary facilitators of 
cell growth and proliferation [15].  
Endocrine therapies for breast cancer 
Since ERα-positive breast cancers rely on estrogen signaling for proliferation, the most 
effective strategy to stop or slow the growth of these hormone-sensitive tumors is to block 
estrogen action in the tumor using endocrine therapy. Current endocrine therapies for ERα-
positive breast cancer include: tamoxifen, the selective estrogen receptor modulator that 
antagonizes ERα function; fulvestrant, the pure anti-estrogen that degrades/downregulates ERα; 
and the more recent standard of care – aromatase inhibitors (AIs).  
The aromatase enzyme (a cytochrome P450 heme-containing protein) is required for the 
synthesis of estrogen via aromatization of androgens such as testosterone [16]. Circulating levels 
of estrogen decrease as a woman enters menopause, since there is no longer production of 
estrogen by the ovaries. Thus, it is the local synthesis of estrogen by breast adipose tissue that 
plays a large role in the growth and survival of ERα-positive breast tumors [17]. Inhibition of 
aromatase activity in this adipose tissue is a rational treatment strategy to suppress estrogen 
production in the breast, thus inhibiting tumor growth. 
Currently, there are three FDA-approved oral AIs in clinical use for the treatment of 
postmenopausal women with hormone receptor-positive breast cancer. These AIs can be divided 
into two categories: steroidal (exemestane) and non-steroidal (anastrozole, letrozole). There has 
been great interest in the development of AIs since it has been observed in clinical trials that they 
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can be more tolerable than tamoxifen, and are usually more effective or equivalently effective in 
clinical response rate and median time to progression [18]. Indeed, letrozole, anastrozole, and 
exemestane have all been shown to suppress circulating estrogen levels in post-menopausal 
breast cancer patients by more than 97% [19, 20]. 
Resistance to aromatase inhibitors 
Unfortunately, the majority of patients treated with AIs are either intrinsically resistant or 
acquire resistance over time, leading to disease progression and death. Objective response rates 
for letrozole and anastrozole have been reported as 55% and 37%, respectively, indicating that 
nearly half of patients treated with non-steroidal AIs have innate resistance [21, 22]. In addition, 
nearly all breast cancers that show an initial response to AIs eventually develop an acquired 
resistance to the therapy [23]. There are several pathways that are implicated in the acquired AI-
resistant phenotype. These include the MAPK [24], EGFR (epidermal growth factor receptor) 
[25], and PI3K pathways (Fig. 2) [26]. ERα has also been shown to play a role in AI resistance, 
in the form of a constitutively active ligand-independent mutant ERα [27], via different genome 
binding patterns [28], or simply by modified expression levels [29]. In fact, one study reveals 
that ligand-independent ERα activation is required for the development of an AI-resistant 
phenotype in the MCF-7aro (aromatase-overexpressing) cell line [30]. The phosphorylation of 
ERα by MAPK (Ser118) and Akt (Ser167) is often essential for the ligand-independent action of 
ERα, as discussed previously (Figs. 1, 2) [10, 11].  
Since the mechanism by which AIs induce death of ERα-positive breast cancer cells often 
involves apoptosis, a disturbance in the balance of pro- and anti-apoptotic genes could also play 
a role in resistance to AI treatment (Fig. 2) [31]. Indeed, this imbalance has been shown in an 
aromatase-expressing MCF-7 cell line with a mutant ERα gene (K303R) [32]. The K303R 
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mutation was shown to cause resistance to both tamoxifen and the AI anastrozole, and these 
K303R MCF-7/Aro cells have an increase in the Bcl-2 (anti-apoptotic)/Bax (pro-apoptotic) ratio, 
which is further exacerbated upon treatment with anastrozole [32].  
The clonally selected LTED (long-term estrogen deprived) models MCF-7:5C and MCF-
7:2A, used in our lab, have also revealed some of the genetic reprogramming that occurs when 
breast tumor cells are deprived of estrogen long term [33]. Both of these cell lines were derived 
from MCF-7 cells cultured in phenol red-free media (phenol red has estrogenic activity) 
containing estrogen-free serum for 8 months, followed by two rounds of limited dilution cloning 
[34, 35]. A summary of the characteristics that these cells display can be found in Table 1. 
Jiang et al. first described the MCF-7:5C cells in 1992, indicating that they have the 
following characteristics: no significant alterations in ERα, loss of estrogen-stimulated PR 
expression, same ability as MCF-7 to bind ERE, less ERE reporter activity, and no response to 
Figure 2. Mechanisms of aromatase inhibitor resistance in breast cancer cells. The mechanisms of AI 
resistance often involve growth factor pathway upregulation. The enhanced activity of growth factors such as 
MAPK can result in estrogen-independent phosphorylation and activation of ERα. In addition to growth factor 
signaling, interferon response genes and anti-apoptotic proteins have also been shown to have increased 
expression in AI-resistant cells. 
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treatment with estrogen, fulvestrant, or tamoxifen [34]. Since then, it has been well-established 
that the MCF-7:5C cells undergo apoptosis following estrogen treatment when they are cultured 
in media containing charcoal-stripped fetal bovine serum instead of the original media which 
contained charcoal-stripped calf serum (Table 1) [36, 37].  
Characteristic Cell Line(s) Reference(s) Comments 
Cell line first described 5C [34] Publication in 1992 
Cell line first described 2A [35]  Publication in 1995 
Express 77 kDa ERα 2A [38-40] Originally described as 80 kDa 
Estrogen-induced apoptosis 5C [33, 36, 37, 
41-49] 
This characteristic is unique to cells 
cultured in RPMI media containing 
10% charcoal-stripped fetal bovine 
serum. 
Differences in sensitivity to 
estrogen-induced apoptosis 
5C and 2A [33, 50] The MCF-7:2A cells are less 
sensitive to estrogen-induced 
apoptosis than the MCF-7:5C cells. 
BSO (Buthionine Sulfoximine) 
sensitization to estrogen-
induced apoptosis 
2A [51, 52]  
Identification of proteins 
involved in estrogen-
independent growth or 
increased aggression 
5C [53] 
[54] 
[55] 
[49] 
PKCα 
PEDF 
cMYC via CDK9 
IFITM1 
Identification of proteins 
involved in estrogen-
independent growth or 
increased aggression 
5C and 2A [56] CEACAM6 
Unique miRNA expression 2A [57] miR-125b 
Table 1. Characteristics of clonally-derived, long-term estrogen deprived MCF-7 cells – MCF-7:5C (5C) 
and MCF-7:2A (2A) 
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The MCF-7:2A cells were first described in 1995 by Pink et al. as an additional model of 
breast cancer cells that exhibit estrogen-independent growth [35]. In this first paper, MCF-7:2A 
cells were described as having the following characteristics: expression of an 80 kDa ERα in 
addition to wild type (Table 1), increased ERE reporter activity, and decreased growth upon 
treatment with fulvestrant and tamoxifen [35]. The larger ERα protein detected in these MCF-
7:2A cells has since been described as a 77 kDa protein that does not play a functional role in the 
cells in terms of estrogen-mediated action, but may interfere with normal ERα activity [38-40].  
In our lab, we have confirmed that the MCF-7:5C and MCF-7:2A cell lines have gained 
the ability to grow in an estrogen-independent manner, unlike their parental cell line, MCF-7, 
whose growth is estrogen-dependent (Fig. 3A). We have shown that our LTED cells also express 
Figure 3. Phenotype of estrogen-dependent MCF-7 cells compared to estrogen-independent LTED MCF-
7:5C and MCF-7:2A cells. (A) The MCF-7:5C and MCF-7:2A cells have gained the ability to proliferate in 
estrogen-deprived conditions, whereas the MCF-7 cells have significantly decreased proliferation in these 
conditions. (B) The basal expression of ERα is increased in the MCF-7:5C, and even more so in the MCF-7:2A 
cells compared to the MCF-7 cells. (C) The ability of the MCF-7:5C and MCF-7:2A cells to migrate through a 
transwell is significantly increased compared to MCF-7, indicating an increased ability to migrate. 
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ERα at higher levels than the MCF-7 cells (Fig. 3B), and are more aggressive – as indicated by 
their increased ability to migrate through a transwell (Fig. 3C). 
Notably, recent findings from our lab have identified a critical role for interferon-
stimulated genes in the estrogen-independent growth of the LTED MCF-7:5C cells (Fig. 2). 
Interferons are cytokines secreted by immune cells in response to viral infection or other 
pathogens [58]. One of these interferon-stimulated genes, IFITM1 (interferon induced 
transmembrane protein 1), has been shown to be markedly overexpressed (> 25-fold) in LTED 
MCF-7:5C breast cancer cells and AI-resistant human breast tumors (Table 1) [49]. Normally 
IFITM1 is important for inhibiting viral infection of cells, but it has also been associated with 
progression of cancers such as colorectal cancer and head and neck cancer [59-61].  
Interestingly, we have found that overexpression of IFITM1 is associated with enhanced cell 
survival, proliferation, and invasiveness of LTED breast cancer cells, and knockdown of IFITM1 
induces cell death and blocks the ability of the MCF-7:5C cells to migrate and invade [49]. 
microRNAs and breast cancer 
microRNAs (miRNAs) are small 18-22 base pair RNA molecules that regulate the 
expression of target mRNAs by inhibiting translation or degrading the transcripts [62]. After 
miRNA genes are initially transcribed by RNA polymerase II, a process regulated by 
transcription factors and nuclear receptors, the transcripts undergo significant processing both in 
the nucleus and cytoplasm  (Fig. 4) [63]. First, the pri-miRNA sequence is cleaved in the nucleus 
by Drosha, a class 2 RNase III enzyme that works in conjunction with DGCR8 (DiGeorge 
syndrome chromosomal region 8). The resulting pre-miRNA hairpin is exported from the 
nucleus to the cytoplasm via Exportin 5 where it is further cleaved by Dicer, another member of 
the RNase III family, resulting in a short double strand piece of RNA. The two strands of the 
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RNA then separate into the passenger strand, which often gets degraded, and the mature miRNA 
strand, which binds to argonaute (Ago) proteins to form the RISC (RNA-induced silencing 
complex) [62]. The miRNA of the RISC guides the complex to the 3’UTR of its target mRNAs. 
Perfect or near-perfect complementarity of the miRNA to the target mRNA stimulates Ago2 in 
the RISC to degrade the mRNA [64]. However, if there is only partial complementarity, the 
translation of the mRNA will be inhibited. 
  Expression profiles of miRNA in breast tumor samples have been correlated with 
biopathologic features such as hormone receptor status and proliferation index, and are used to 
distinguish between basal and luminal subtypes [65, 66]. For example, miRNAs overexpressed 
in basal, ERα-negative primary breast cancers include miR-150, which has been shown to 
promote breast cancer growth [67], and miR-135b, which correlates with early metastasis of 
Figure 4. Standard pathway by which 
miRNAs are processed and loaded onto 
RISC to regulate gene expression. 
Regulation of miRNA expression is 
controlled at the miRNA promoter by 
transcription factors (TF) and nuclear 
receptors (NR). After transcription, the pri-
miRNA is processed inside the nucleus by 
Drosha and DGCR8 to form pre-miRNA – a 
hairpin miRNA. Exportin 5 exports the pre-
miRNA from the nucleus into the cytoplasm 
where it gets cleaved further by Dicer, 
resulting in a short double strand piece of 
RNA. These strands are separated into the 
passenger strand, which often gets degraded, 
and the mature strand, which is loaded onto 
the RISC (RNA-induced silencing complex) 
for action on target mRNA. If the mature 
miRNA sequence is a perfect or near-perfect 
match to its target mRNA 3’UTR, the 
transcript is degraded by Ago2. However, if 
there are enough mismatches between the 
miRNA and its target mRNA, the result is 
inhibition of translation. 
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breast cancer cells [68]. miRNAs overexpressed in luminal, ERα positive breast cancers include 
miR-126 and miR10a, which are associated with an increase in patients’ relapse-free time after 
tamoxifen treatment [69].  
Beyond the use of expression profiles, specific miRNAs have been associated with 
regulation of genes involved in breast cancer. The let-7 miRNA family has been shown to 
regulate the self-renewal capacity of breast tumor-initiating cells derived from cell lines and 
primary patient tumors by inhibition of HRAS (Harvey rat sarcoma viral oncogene homolog) and 
HMGA2 (high mobility group AT-hook2), genes involved in self-renewal and differentiation, 
respectively [70]. miR-21, which targets many genes, including PTEN (phosphatase and tensin 
homolog), was identified to be upregulated in primary patient samples of invasive breast cancer 
compared to normal breast tissue by miRNA in-situ hybridization staining [71]. Two miRNAs, 
miR-373 and miR-520c, are considered metastasis-promoting miRNAs and are shown to be 
upregulated in lymph node metastases compared to primary tumor samples [72]. Promotion of 
tumor invasion and metastasis by miR-373 and miR-520c is likely achieved via suppression of 
the CD44 gene, which codes for a hyaluronan receptor and has been identified as a metastasis 
suppressor in breast cancer [73].  
microRNAs and resistance to aromatase inhibitors 
There has been little research done on the topic of miRNAs involved in AI resistance, but 
recent studies have begun to shed light on the field. Masri et al. conducted a miRNA expression 
analysis for four AI-resistant cell models, all derived from MCF-7aro (aromatase-
overexpressing) cells [74]. MCF-7aro cells were treated with testosterone and each of three AIs 
until they acquired resistance. An LTED cell line (LTEDaro) was also derived from the MCF-
7aro cells for comparison. When compared to LTEDaro cells and cells treated only with 
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testosterone, letrozole-resistant cells overexpressed miR-128a, suggesting it plays a role in AI 
resistance. miR-128a is associated with breast cancer aggressiveness, and is involved in 
regulation of TGFβR1 (transforming growth factor beta receptor 1) [75]. Inhibition of miR-128a 
in the letrozole-resistant cells led to re-sensitization to TGFβ growth-inhibitory effects [74]. It is 
also interesting to note that the miRNA expression profiles for the cells resistant to the steroidal 
AI (exemestane) and the non-steroidal AIs (letrozole, anastrozole) were distinct from one 
another, and the AI-resistant cells were distinct from the LTEDaro model of AI resistance, which 
supports the idea that multiple mechanisms of acquired resistance to AIs may exist [74]. 
In addition to the confirmed role of miR-128a, Masri et al. also briefly mentioned the 
downregulation of miR-125b in the letrozole-resistant, anastrozole-resistant, and exemestane-
resistant cells compared to the LTEDaro cells [74]. A recent study in MCF-7:2A (LTED) cells 
by Bailey et al. confirms downregulation of miR-125b in AI-resistant cells and also indicates 
relevance of the other members of its miRNA cluster (a cluster is defined as miRNAs that are 
transcribed in one primary transcript and cleaved into individual hairpin loops in the nucleus by 
Drosha) [57]. The let-7c/miR-99a/miR-125b miRNA cluster encoded within the LINC00487 
gene was shown to be downregulated in MCF-7:2A cells compared to MCF-7 parental cells. A 
luciferase reporter assay confirmed that let-7c and miR-125b bind the HER2 (human epidermal 
growth factor receptor 2) 3’UTR, but it was revealed that while miR-125b directly regulates 
HER2 expression via the binding of HER2 3’UTR, let-7c regulation of HER2 is indirect via the 
inhibition of Dicer, one of the proteins involved in miRNA function [57]. Upon analysis of 
clinical data from The Cancer Genome Atlas, it was clear that let-7c and HER2 were inversely 
correlated in Luminal A breast tumors and that low expression of the let-7c/miR-99a/miR-125b 
cluster was associated with worse overall survival compared with patients who had high 
expression of this cluster [57]. 
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Interestingly, the most recent study by Vilquin et al., which also surveyed the miRNAs 
associated with AI resistance, contains results that conflict with the other two studies [57, 74, 
76]. While Masri et al. and Bailey et al. found a downregulation of miR-125b in their AI-
resistant models, Vilquin et al. showed an upregulation of miR-125b in AI-resistant models 
derived by long term treatment of MCF-7aro cells with letrozole (Res-Let) and anastrozole (Res-
Ana) [76]. In fact, this study showed that miR-125b overexpression is sufficient to confer 
resistance to AIs in MCF-7aro cells and this is accomplished by activation of the Akt/mTOR 
pathway [76]. Analysis of primary breast tumors revealed that high levels miR-125b expression 
were associated with shorter relapse-free survival in luminal A breast cancers [76]. 
Another study of miRNA expression in MCF-7 cells revealed several miRNAs that were 
increased following letrozole treatment [77]. Perhaps the most interesting result was the 
upregulation of let-7f upon treatment with letrozole, as it inhibits the expression of the aromatase 
gene (CYP19A1) [77]. This study may reveal a mechanism of resistance similar to that of 
tamoxifen resistance – loss of the inhibitor’s target. Just as tamoxifen resistance occurs in 
conjunction with absence of ERα, resistance to AIs may eventually develop due to pronounced 
loss of aromatase expression due to upregulation of certain miRNAs upon treatment. 
In the past couple of decades, conducting genome- and transcriptome-wide expression 
analyses of cancer cells has become popular, and the development of microarrays and next-
generation sequencing technologies have made these analyses possible. Next-generation 
sequencing has outpaced traditional sequencing as a faster and more accurate tool, and is used 
for many applications including DNA sequencing, transcriptome analysis, chromatin 
immnuoprecipitation analysis, and small RNA discovery and analysis. We have conducted next-
generation sequencing of the miRNAs from three breast cancer cell lines – one ERα-positive line 
that is estrogen-dependent (MCF-7), and two ERα-positive LTED models of estrogen-
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independent growth (MCF-7:5C and MCF-7:2A), which are considered models of the AI-
resistant phenotype. Differential expression analysis revealed the differences in miRNA 
expression between the MCF-7 cells and the LTED MCF-7:5C and MCF-7:2A cells. Of the 
miRNAs that were determined to be upregulated in both MCF-7:5C and MCF-7:2A vs. MCF-7, 
we proceeded to conduct in vitro work to determine the potential role of miR-181a in estrogen-
independent growth. 
 miR-181a has been described in multiple cancers, such as hepatocellular carcinoma [78-
80], acute myeloid leukemia [81], cervical cancer [82], pancreatic cancer [83], and colorectal 
cancer [84, 85]. In addition, miR-181a plays a significant role in breast cancer aggressiveness 
[86], response to chemotherapy [87], metastasis [88], and formation of mammospheres [89]. The 
clinical significance of miR-181a in breast cancer has also been described by comparing miRNA 
expression in serum samples of 205 women who eventually developed breast cancer vs. 205 
women who remained breast cancer free [90]. This study revealed an increase in the expression 
of 21 miRNAs in the samples from women who developed breast cancer, including miR-181a 
(15% overexpressed, p = 0.05) [90]. Since the serum samples were taken before the women 
developed breast cancer, miR-181a could potentially be used as a biomarker for early detection 
of breast cancer. 
Transcription of the miR-181a-1/miR-181b-1 cluster on chromosome 1q32.1 has been shown 
to be regulated by MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma 
derived homolog), which binds directly to the miR-181a promoter [91]. The miR-181a promoter 
also contains multiple binding sites for the β-catenin/Tcf4 transcription factor complex, which 
has been correlated with enhanced expression of miR-181a, and Tcf4 was shown by chromatin 
immunoprecipitation to bind the miR-181a promoter [79]. In addition to regulation by MYCN 
and β-catenin/Tcf4, miR-181a expression has been shown to be upregulated by TGF-β, and 
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HER2 [79, 88, 92], and inhibited by NF-κB and estrogen signaling via ERα [89, 93]. In the 
microarray done by Masri et al., miR-181a was shown to be overexpressed in the LTEDaro cells 
compared to parental MCF-7aro, which confirms a potential role of miR-181a in the estrogen-
independent phenotype [74]. There are many targets of miR-181a, some of which play a role in 
regulating DNA damage repair, such as ATM (ataxia telangiectasia mutated) [86] and BRCA1 
(breast cancer 1, early onset) [94]. Others, such as PTEN, PR (progesterone receptor), and Bim, 
are known to play roles in growth and apoptosis of cancer cells. 
It is clear that there is a role for miRNAs in the development of resistance to AIs, as modeled 
by estrogen-independent and AI-resistant cells, but also clear is the need for more work to further 
characterize the miRNA expression profiles of AI-resistant cell models and tumors. Work in the 
field of miRNAs and AI resistance will contribute to the identification of biomarkers and novel 
therapeutic targets for AI-resistant breast tumors. In this study, we hypothesized that our 
estrogen-independent cell models of AI-resistance have unique miRNA profiles compared to 
parental estrogen-dependent cells, and that miR-181a has a specific role in the development of 
this estrogen-independent phenotype. This hypothesis was tested by the following specific aims: 
I. To characterize the miRNA profiles of MCF-7 breast cancer cells and the long-term 
estrogen-deprived MCF-7:5C and MCF-7:2A cell models of aromatase inhibitor 
resistant breast cancer. 
II. To determine the role of miR-181a in the estrogen-independent growth of the MCF-
7:5C and MCF-7:2A long-term estrogen-deprived cell models of aromatase inhibitor 
resistant breast cancer.  
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Materials and Methods 
Reagents 
RPMI-1640, fetal bovine serum (FBS), antibiotic/antimycotic solution (containing 10,000 
U/mL penicillin and 10 mg/mL streptomycin, 25 µg/mL of Fungizone®), non-essential amino 
acids (NEAA), L-glutamine, and TrypLE (containing trypsin and EDTA) were all obtained from 
Invitrogen (Grand Island, NY). Insulin (from bovine pancreas) and 17β-estradiol (E2) were 
obtained from Sigma-Aldrich (St. Louis, MO). E2 was dissolved in 100% ethanol at a stock 
concentration of 1 mM and stored at -20°C. Fulvestrant (ICI) was dissolved in 100% ethanol at a 
stock concentration of 1mM and stored at -20°C. 
Primary antibodies were used against the following proteins: BRCA1 (1:200, Santa Cruz 
#642), ATM (1:200, Santa Cruz #23921), PTEN (1:1000, Cell Signaling #9559), ERα (1:200, 
Santa Cruz #544), and β-actin (1:15,000, Sigma-Aldrich #A5441). HRP-conjugated secondary 
antibodies were used against rabbit (Cell Signaling #7074) or mouse (Cell Signaling #7076). 
Cell Culture Conditions 
The ERα-positive hormone-dependent human breast cancer cell line MCF-7 was 
originally obtained from the American Type Culture Collection (Manassas, VA) and was 
maintained in RPMI-1640 medium supplemented with 10% FBS, 2 mM L-glutamine, penicillin 
(100 U/mL), streptomycin (100 µg/mL), Fungizone® (25 ng/mL), 1× NEAA (Invitrogen), and 
bovine insulin at 6 ng/mL (Sigma-Aldrich). The MCF-7:5C and MCF-7:2A cell lines were 
developed by long term estrogen deprivation of the MCF-7 parental cells followed by clonal 
selection [34, 35].  The MCF-7:5C and MCF-7:2A cells were maintained in phenol red-free 
RPMI-1640 supplemented with 10% dextran-coated charcoal-stripped FBS, 2 mM L-glutamine, 
penicillin (100 U/mL), streptomycin (100 µg/mL), Fungizone® (25 ng/mL), 1× NEAA 
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(Invitrogen), and bovine insulin at 6 ng/mL (Sigma-Aldrich). Cells were cultured at 37°C in 5% 
CO2 and were subcultured every three to four days. 
RNA Isolation 
Total RNA was extracted from breast cancer cell lines, in duplicate, for sample 
submission to the sequencing facility. Cells were plated on 60mm plates and grown 48 hours at 
37°C, 5% CO2. Cells were harvested immediately and lysed with Lysis/Binding Buffer (mirVana 
kit, Ambion). RNA extraction was carried out using the mirVana total RNA isolation protocol 
(Ambion). RNA concentration, 260/230 ratios, and 260/280 ratios were measured using a 
NanoDrop system immediately after isolation. Samples were kept in -80°C. Dilutions of these 
samples were prepared for submission to the sequencing core – 300ng/μL, 10μL total – and were 
analyzed on the Agilent 2100 Bioanalyzer for RNA integrity. 
Library Preparation 
Total RNA (1μg) was used to initiate the TruSeq Small RNA library preparation protocol 
(Illumina #RS200-0012 kit A). The small RNA fraction was ligated with 3’ and 5’ RNA adapters 
followed by a reverse transcription reaction and PCR amplification using 11 cycles of 
amplification. Size selection and purification of the cDNA library construct was conducted using 
3% marker H gel cassettes on the Pippin Prep size fractionation system (Sage Science). The 
Agilent 2100 Bioanalyzer was used with the High Sensitivity DNA kit (Agilent #5067-4626 ) or 
the DNA1000 kit (Agilent #5067-1504) to validate the purified libraries. Libraries were 
quantified on the Illumina ECO Real Time PCR System using KAPA SYBR Universal Library 
Quant kit – Illumina (KAPA Biosystems KK4824). Following quantification, libraries were 
adjusted to a 2nM concentration and pooled for multiplexed sequencing.  
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Rapid Read Next-Generation Sequencing 
miRNA sequencing was performed using the Illumina HiSeq2500 Sequencing System at 
the University of Kansas Medical Center – Genomics Core (Kansas City, KS). Libraries were 
denatured and diluted to the appropriate pM concentration (based on qPCR results) followed by 
clonal clustering onto the sequencing flow cell using the TruSeq Rapid Single Read (SR) Cluster 
Kit-HS (Illumina GD402-4001). The clonal clustering procedure was performed using the 
automated Illumina cBOT Cluster Station.  The clustered flow cell was sequenced on the 
Illumina HiSeq 2500 Sequencing System in Rapid Read mode with a 1x50 cycle read and index 
read using the TruSeq Rapid SBS kit-HS (Illumina FC402-4002). Following collection, sequence 
data was converted from .bcl file format to FASTQ files and de-multiplexed into individual 
sequences for further downstream analysis. 
Bioinformatic Analysis 
To discover the miRNAs within the FASTQ files, the program miRDeep2 [95] was used. 
The reads were mapped to the hg19 human genome and, using a probabilistic model that scores 
reads based on structure and signature, the reads were identified using the microRNA database 
and novel miRNAs were predicted. Next, the Bioconductor package edgeR [96] was employed 
to normalize each miRNA read count to the total number of sequencing reads for each sample, 
and to determine the differential miRNA expression between the cell lines. The list of 
differentially expressed miRNAs was refined by using the following parameters: fold change 
greater than 1.5 and false discovery rate less than 0.05. Lists of genes targeted by the miRNAs 
were compiled by use of miRTarBase [97], a database of validated miRNA-target interactions.  
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miRNA Real-time quantitative PCR (qPCR) 
For miRNA qPCR, total RNA was isolated from cultured cells using the mirVana RNA 
isolation kit (Ambion) according to manufacturer’s protocol. cDNA was synthesized using the 
miRCURY LNA Universal cDNA synthesis kit II (Exiqon) using 10 ng of total RNA. qPCR was 
performed to evaluate the miRNA levels using the miRCURY ExiLENT SYBR® Green Master 
Mix (Exiqon), primer mix (Exiqon), and a 1:40 dilution of cDNA. The primer mixes were as 
follows: miR-103a-3p, #204063; miR-181a-5p, #204566; miR-221-3p, #204532; miR-222-3p, 
#204551; miR-127-3p, #204048.  
Western Blot 
Cells were harvested in cold 1X PBS and cell pellets were lysed in 100μL of lysis buffer 
(RIPA buffer, 1% protease inhibitor cocktail, and 1% phosphatase inhibitor). Lysates were 
sonicated and centrifuged to collect protein. The protein in each sample was quantified using the 
Bio-Rad protein assay (Bio-Rad) and samples were prepared for Western blot. 4-12% SDS-
polyacrylamide gels were used to separate the proteins and the proteins were transferred to 
polyvinylidine difluoride membrane for 220 minutes at 30V on ice. The membranes were 
blocked in 5% non-fat milk prepared in Tris-buffered saline with Tween-20 (TBST). The 
membranes were then incubated in primary antibody, followed by three washes in TBST, and 
then incubated in the horseradish peroxidase (HRP)-conjugated anti-rabbit or anti-mouse IgG. 
Bands of protein on the membrane were detected by addition of Amersham ECL Plus Western 
blotting detection reagents. 
Drug and Radiation Treatments 
For treatment with taxol, a 10 μM working stock was prepared in ethanol from a 10 mM 
stock and kept in -20°C. The 10 μM stock was diluted in media for treatments as needed. Dose 
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response curves required dilutions of 0.01, 0.1, 1.0, 10, and 100 nM. For treatment with olaparib 
(a gift from Dr. Jeremy Chien, University of Kansas Medical Center), a 50 µM stock was kept in 
-20°C and diluted in media for treatments as needed. For the treatment with multi-fraction dose 
ionizing radiation, cells were exposed to 2.5 Gy once per day for four consecutive days. 
Proliferation Assays 
The Cell Titer Blue® (Promega) assay was performed according to manufacturer’s 
protocol to measure the viability of cells after treatment with chemotherapeutic drugs and 
radiation. Cells were seeded 5,000 per well in 96 well culture-treated plates and treatment was 
applied 24 hours later, after the cells had attached to the plate. Cell Titer Blue ® solution was 
diluted 1:5 in cell culture medium, added to cells, and cells were incubated at 37°C for 2 hours. 
Fluorescence was measured at 560/590 nm and graphed as a percentage of the untreated cells. 
The CyQUANT DNA quantification assay was performed according to manufacturer’s 
protocol to measure the proliferation rate of cells after transfection with the miR-181a inhibitor. 
Cells were seeded 5,000 per well in 96 well culture-treated plates and transfected 24 hours later, 
after the cells had attached to the plate. CyQUANT dye binding solution was prepared, added to 
cells, and cells were incubated at 37°C for 15 minutes. Fluorescence was measured at 485/530 
nm and graphed as a percentage of the untreated cells. 
Colony Formation Assays 
Cells were plated in 12-well culture-treated plates at 500 cells per well and allowed to 
attach overnight. Transfection with miR-181a mimic or taxol treatments were done as indicated, 
and the cells were allowed to grow for 6 days uninterrupted. Medium was removed from each 
well and cells were rinsed with 1X PBS. Fixation and staining of colonies was done with a 
mixture of 0.5% crystal violet in 1:7 acetic acid:methanol for 2 minutes. A series of washes with 
1X PBS was performed and images were taken and quantified using ImageJ software. 
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Transfections 
For miR-181a knockdown experiments, cells were transfected with a mirVana miR-181a 
inhibitor or negative control inhibitor #1 (Ambion). Cells were transfected with 12.5nM of 
inhibitor using Lipofectamine 2000 according to the manufacturer’s protocol in OPTI-MEM. 
Media was changed back to the normal complete media for each cell line 24 hours after 
transfection. Transfection efficiency was determined by qPCR for miR-181a expression.  
For miR-181a mimic experiments, cells were transfected with a mirVana miR-181a 
mimic or negative control #1 (Ambion). Cells were transfected with 20nM of mimic using 
Lipofectamine 2000 according to manufacturer’s protocol in OPTI-MEM. MCF-7 cells were 
plated for this experiment in estrogen-containing media and either kept in estrogen containing 
media (labeled E2-containing in figures), or switched to estrogen-deprived media (labeled E2-
deprived in figures) 24 hours after transfection. Transfection efficiency was determined by qPCR 
for miR-181a expression. 
For ERα knockdown experiments, cells were transfected with siRNA targeting ERα 
(siER) or a non-targeted siRNA (siCtrl) (Santa Cruz Biotechnology). Cells seeded in 6 well 
plates were transfected with 5nM of siRNA using Lipofectamine 2000 according to the 
manufacturer’s protocol in OPTI-MEM. Transfection efficiency was determined by Western blot 
for ERα protein expression. 
Statistical Analysis 
All statistical comparisons of data were done using GraphPad Prism® software. Unpaired 
two-tailed t tests with 95% confidence intervals were performed for each set of data, and p-
values were reported on the graphs.  
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Results 
miRNAs differentially expressed in LTED versus MCF-7 cells 
miRNA expression profiles were obtained for MCF-7 breast cancer cells, as well as the 
LTED, clonally-derived cell lines MCF-7:5C and MCF-7:2A by next-generation sequencing. 
The read counts were normalized by total reads and mapped to the hg19 reference genome using 
the program miRDeep2 [95]. miRNAs that were differentially expressed between the cell lines 
were discovered using the bioinformatic tool edgeR [96] (Fig. 5A). Fold change was analyzed 
Figure 5. Next-generation sequencing of miRNAs reveals differences between estrogen-dependent and 
estrogen-independent cells. Rapid read 50-cycle next-generation sequencing of our estrogen-dependent MCF-7 
cells and estrogen-independent MCF-7:5C and MCF-7:2A cells was conducted, and differential expression 
analysis was performed. (A) A partial heat map of miRNA expression in MCF-7 cells vs. the MCF-7:5C and 
MCF-7:2A cells. (B) 338 miRNAs are differentially expressed between MCF-7 and MCF-7:5C cells, while 241 
miRNAs were differentially expressed between MCF-7 and MCF-7:2A cells. 
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for each of the following comparisons: MCF-7 vs. MCF-7:5C, MCF-7 vs. MCF-7:2A, MCF-
7:5C vs. MCF-7:2A, and MCF-7 vs. [MCF-7:5C and MCF-7:2A]. When compared to MCF-7, 
MCF-7:5C had 338 differentially expressed miRNAs while MCF-7:2A had only 241 (Fig. 5B). 
Individual miRNA profiles were defined for each of the LTED cell lines, and there were 126 
miRNAs that both LTED cell lines expressed in common, relative to MCF-7 (Table 2). The 126 
miRNAs that were differentially expressed in both MCF-7:5C and MCF-7:2A include miRNAs 
that were also identified by the previous studies of miRNA expression in AI-resistant cells 
(Table 3), which indicates their relevance for further study [74, 98].   
  
Table 2. microRNAs significantly differentially expressed in LTED cells vs. MCF-7 
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miRNAs differentially expressed in MCF-7:5C versus MCF-7:2A cells 
Upon further bioinformatic analysis, it was apparent that the LTED cells had very unique 
expression profiles compared to one another, indicating that they have adapted to an estrogen-
depleted environment through potentially different mechanisms (Fig. 6). In MCF-7:5C cells, 
which have lost expression of PR, a group of miRNAs on chromosome 14 is upregulated (Table 
4). This upregulated group, which includes miR-127, miR-654, miR-889 and others, has been 
shown to be associated with Luminal B (ER+/PR-) breast cancer, consistent with the hormone 
receptor status of the MCF-7:5C cells [99]. The oncogenic, estrogen-responsive miR-17/92 
cluster on chromosome 13 is upregulated in the MCF-7:2A cells (Table 5) and these miRNAs 
target proteins including PTEN, p21, and Bim. We chose one miRNA from the chromosome 14 
region that was upregulated in the MCF-7:5C cells – miR-127 – and validated its expression by 
qPCR. Due to undetectable levels of miR-127 in the MCF-7 and MCF-7:2A cells, it was not 
possible to determine an exact relative expression value, but miR-127 was detected in the MCF-
7:5C cells which confirms that miR-127 levels are highest in MCF-7:5C cells. 
  
Table 3. miRNAs found to be upregulated in both LTED cell lines are also upregulated in the AI-resistant 
cell lines in other studies published on miRNAs and AI resistance 
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Figure 6. The miRNA expression of two LTED cell lines is unique. Analysis of the miRNAs upregulated 
only in MCF-7:5C or MCF-7:2A reveals miRNAs unique to each cell line. In the MCF-7:5C cells, miRNAs on 
chromosome 14q32 are upregulated, but these are not necessarily components of a single transcript. Whereas, 
the chromosome 13q31 cluster that is upregulated in MCF-7:2A cells encodes six miRNAs that are transcribed 
together and cleaved into individual pre-miRNA during processing of the RNA transcript in the nucleus. 
 
Table 4. miRNAs upregulated in MCF-7:5C cells vs. MCF-7:2A cells include miRNAs from a cluster 
encoded on chromosome 14. 
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miR-181a is overexpressed in MCF-7:5C cells 
In order to characterize the miRNAs expressed in these LTED cells, we found it ideal to 
begin with those that were differentially expressed in both MCF-7:5C and MCF-7:2A, compared 
to MCF-7. According to the sequencing data, a few of these shared miRNAs included miR-181a, 
miR-221, and miR-222. The qPCR levels of miR-181a were validated in the MCF-7:5C cells as 
very similar to the sequencing data (7-fold vs. 5.8-fold overexpressed, respectively), as were the 
levels of miR-221 (13.2-fold vs. 13.4-fold underexpressed) and miR-222 (18.4-fold vs. 17.3-fold 
underexpressed) (Fig. 7). While the MCF-7:2A cells didn’t show as many similarities between 
qPCR levels and sequencing levels for miR-221 or miR-222, the levels of miR-181a were 
validated as similar to the sequencing expression (3.4-fold vs. 2.3-fold overexpressed) (Fig. 7).  
 
Table 5. miRNAs upregulated in MCF-7:2A cells vs. MCF-7:5C cells include miRNAs from a cluster 
encoded on chromosome 13, as well as many miRNAs that are upregulated by estrogen signaling. 
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Regulation of miR-181a by estrogen and estrogen receptor alpha 
Estrogen has previously been shown to downregulate expression of miR-181a [93]. Thus, 
the overexpression of miR-181a in our MCF-7:5C cells cultured in the absence of estrogen, 
compared to MCF-7 cells cultured with estrogen, may simply be an artifact of media conditions. 
However, when miR-181a expression was measured in MCF-7 cells that were estrogen-deprived 
for 120 hrs (MCF-7Y), there was only a slight increase in expression, not nearly as high as the 
expression of miR-181a in the MCF-7:5C cells. To analyze this regulation of miR-181a 
expression further, the level of miR-181a was measured following treatment with 17β-estradiol, 
degradation of ERα by Fulvestrant (ICI), and knockdown of ERα by siRNA.  Treatment of 
MCF-7Y cells with 17β-estradiol decreased miR-181a levels, and degradation of ERα by ICI 
blocked this regulation by estrogen – indicating the estrogen regulation of miR-181a expression 
is ERα-dependent (Fig. 8A). The estrogen-mediated downregulation of miR-181a expression in 
the MCF-7 cells at 48 hours post-treatment was further verified (Fig. 8B). Interestingly, 
Figure 7. Validation of microRNA expression by qPCR. miR-181a expression was greater in the MCF-
7:5C and MCF-7:2A cells, while miR-221/222 is decreased in MCF-7:5C compared to MCF-7. Not shown: 
miR-127 is highly expressed in MCF-7:5C, as measured by qPCR, but was not detectable in MCF-7 and 
MCF-7:2A.  
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however, expression of miR-181a appears to be unaffected by 17β-estradiol treatment in the 
MCF-7:5C cells, indicating the difference in their response to estrogen compared to the estrogen-
dependent MCF-7 cells (Fig. 8B). Even though estrogen doesn’t affect the expression of miR-
181a in MCF-7:5C cells, there could still be estrogen-independent action of ERα to regulate 
miR-181a. Knockdown of ERα by siRNA does in fact allow for an increase in the expression of 
miR-181a in MCF-7:5C cells 48 hours after ERα knockdown (Fig. 8C), indicating that there is 
Figure 8. Estrogen downregulates the expression of miR-181a and this is dependent on action of ERα. (A) 
When MCF-7 cells, normally grown in red (estrogen-containing) media (MCF-7R), are deprived of estrogen for 
120h (MCF-7Y), they still don’t have as high a level of miR-181a as MCF-7:5C cells, and when these MCF-7Y 
cells are treated with 1nM 17β-estradiol (E2), expression of miR-181a decreases back to the same level as MCF-
7R. This E2-downregulation of miR-181a is dependent upon ERα since 1µM ICI treatment, which causes 
degradation of ERα, blocks the E2-downregulation of mir-181a expression. (B) As already seen in A, the MCF-
7Y cells are E2-responsive and decrease miR-181a expression upon E2 treatment (at 48 hrs). However, the MCF-
7:5C cells respond to E2 in a different way, which may not include downregulation of miR-181a expression. (C) 
48 hrs after knockdown of ERα (siER), miR-181a expression significantly increases in MCF-7:5C cells. (D) siER 
knockdown efficiency. 
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potential ligand-independent action of ERα in the MCF-7:5C cells that partially suppresses miR-
181a expression. 
Functional role of miR-181a in estrogen-independent growth 
Since miR-181a expression was validated as being upregulated in both the MCF-7:5C 
and MCF-7:2A cells, we decided to analyze this miRNA for functional relevance in our cells. 
Loss-of-function studies using an inhibitor for miR-181a were used to identify the functional role 
of miR-181a in the MCF-7:5C and MCF-7:2A cells. The miR-181a inhibitor successfully 
decreased the levels of miR-181a in the cells compared to the negative inhibitor control (Fig. 
9A), and the rate of proliferation was affected by this loss of miR-181a expression, as measured 
by CyQUANT DNA quantification. At 48 and 52 hours, the MCF-7:5C cells show a significant 
decrease in proliferation with the miR-181a inhibitor (Fig. 10B), while the MCF-7 and MCF-
7:2A cells seem to be less affected by the loss of miR-181a (Fig. 10A, 10C). 
Figure 9. miR-181a knockdown and overexpression in breast cancer cells. A) Expression of miR-181a is 
decreased when cells are treated with the mirVana miR-181a inhibitor (181a inh). Neg control indicates 
transfection with the mirVana negative control inhibitor #1. B) Expression of miR-181a is increased when cells 
are treated with the mirVana miR-181a mimic (181a mimic). Neg control indicates transfection with the mirVana 
negative control #1. 
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Conversely, a miR-181a mimic was transfected into estrogen-dependent MCF-7 cells, 
which was confirmed by qPCR (Fig. 9B). Two-dimensional colony formation assays of MCF-7 
cells with and without miR-181a mimic reveal a decrease in the number of colonies that grow 
from estrogen-deprived MCF-7 cells compared to those cultured with estrogen, and this is 
rescued when MCF-7 cells are transfected with the miR-181a mimic (Fig. 10D). This trend is 
confirmed by the fact that the MCF-7 cells form smaller colonies in an estrogen-deprived 
environment when compared to estrogen-containing MCF-7, and this is rescued by the 
Figure 10. miR-181a affects ability of MCF-7 and MCF-7:5C cells to proliferate in E2-deprived conditions. 
Proliferation of MCF-7 cells (A) and MCF-7:2A cells (C), as measured by CyQUANT DNA quantification, was 
not significantly affected by inhibition of miR-181a compared to negative control inhibitor-transfected cells. 
However, the proliferation of MCF-7:5C cells (B) was decreased at both 48 and 52 hours upon inhibition of miR-
181a compared to the negative control inhibitor-transfected cells. (D) In addition, colony formation of MCF-7 
cells decreases when the cells are deprived of E2 (neg control red vs. neg control yellow), and a miR-181a mimic 
was sufficient to rescue this decrease in number of colonies formed. While these differences in colony number 
were not significantly different, the size of the colonies (E) was significantly changed between the treatment 
conditions. The MCF-7 cells make smaller colonies when they are E2-deprived, and addition of miR-181a mimic 
results in colonies even larger than the MCF-7 cells in E2-containing media. 
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transfection of the miR-181a mimic (Fig. 10E). These data support the hypothesis that miR-181a 
could have a functional role in the estrogen-independent proliferation of our cells. 
miR-181a and sensitivity of estrogen-independent cells to DNA damage 
miR-181a has been shown to play a role in regulating DNA damage repair proteins such 
as ATM [86] and BRCA1 [94]. Interestingly, the MCF-7:5C cells show a particular sensitivity to 
mitotic arrest and DNA damage by taxol (Fig. 11) and ionizing radiation (Fig. 12A). Thus, the 
idea that miR-181a is sensitizing these LTED MCF-7:5C cells to chemotherapy and DNA 
damaging agents was pursued.  
Figure 11. MCF-7:5C cells are more sensitive to taxol. Treatments with varying concentrations of taxol were 
used to create two separate dose response curves for each of our cell lines – one using the Cell Titer Blue viability 
assay (A) and the other by two-dimensional colony formation (B). The IC50 values were calculated according to 
each dose response curve and are listed in (C). (D) Representative images of colonies for each cell line after taxol 
treatment according to the upper right box of numbers (in nM). 
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First, we measured the protein levels of ATM, BRCA1, and PTEN (all miR-181a targets) 
in our cells following transfection with the miR-181a inhibitor or miR-181a mimic. Western blot 
analysis of ATM, BRCA1, and PTEN protein expression in MCF-7 and MCF-7:5C 48 hours 
after transfection with the miR-181a inhibitor revealed a consistent upregulation of all three 
proteins in the miR-181a-depleted MCF-7:5C cells (Fig. 13A). Treatment of MCF-7 cells with a 
Figure 12. MCF-7:5C cells are more sensitive to DNA damage induced by ionizing radiation, especially 
when miR-181a is inhibited. (A) Multi-fraction dose (MFD) ionizing radiation treatments – 2.5 Gy every day for 
four consecutive days – significantly decreases the viability of MCF-7:5C and MCF-7:2A cells, with the most 
pronounced effect in the MCF-7:5C. (B) Inhibition of miR-181a further decreases the viability of MCF-7:5C cells 
in conjunction with MFD ionizing radiation. 
 
Figure 13. Expression of DNA damage repair proteins is affected by miR-181a. (A) The inhibition of miR-
181a resulted in a slight increase of ATM, BRCA1, and PTEN expression in the MCF-7:5C cells at 48 hours after 
transfection, but this was not consistent in the MCF-7 cells. The overall expression of BRCA1 was higher in 
MCF-7:5C cells. Ctrl, untransfected control; neg, negative control inhibitor; 181i, miR-181a inhibitor. (B) The 
addition of miR-181a mimic (181a) to MCF-7 cells resulted in the decrease of its targets ATM, BRCA1, and 
PTEN compared to negative control-transfected cells (neg) at 48 hours after transfection. 
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miR-181a mimic for 48 hours resulted in downregulation of these same proteins (Fig. 13B), 
indicating that they are in fact targets of miR-181a in our cells.  
Next, we wanted to understand the effect of a miR-181a inhibitor on the sensitivity of our 
MCF-7:5C cells to ionizing radiation. The cells were transfected with miR-181a inhibitor, were 
subject to ionizing radiation for four consecutive days (2.5 Gray per day), and cell viability was 
measured (Fig. 12B). The MCF-7:5C cell viability after this multi-fraction dose radiation was 
decreased further with inhibition of miR-181a (Fig. 12B). This was a peculiar finding given our 
initial hypothesis that miR-181a expression may be what is weakening the DNA damage 
response of our MCF-7:5C cells – we would expect knockdown of miR-181a to either increase 
or not affect the viability of these cells after radiation. 
Finally, olaparib was used to test whether the inhibition of DNA damage repair proteins 
by miR-181a would make the LTED cells more sensitive to a PARP (poly-ADP ribose 
polymerase) inhibitor. MCF-7, MCF-7:5C, and MCF-7:2A cells were treated with olaparib, and 
the IC50 values were calculated from dose response curves (Fig. 14). The IC50 values reveal a 
trend that indicates the MCF-7 cells are most sensitive to the olaparib (IC50 = 23.06 ± 4.12), 
followed by the MCF-7:5C cells (IC50 = 32.08 ± 3.56), and the least sensitive cells MCF-7:2A 
(IC50 = 53.05 ± 5.16), though it should be noted that these results weren’t statistically 
significant.  
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Figure 14. Olaparib treatments reveal possible lack of sensitivity of MCF-7:5C and MCF-7:2A cells to 
PARP inhibitor. Treatment with olaparib revealed a trend that presents the MCF-7 cells as the most sensitive 
to PARP inhibition, while the MCF-7:5C and MCF-7:2A cells were less sensitive, as indicated by IC50 values 
below dose response curve. It should be noted, however, that none of the IC50 values were significantly 
different from the others. 
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Discussion 
The role of miRNAs has been well established in multiple types of cancer, including 
breast cancer [100-102]. In addition to representing a specific molecular profile of certain 
pathological features in breast cancer [66], miRNAs are involved in development of resistance to 
endocrine therapies such as tamoxifen treatment [103-106]. More recently, studies have shown 
that the miRNA profile of breast cancer cells changes when the cells become resistant to AI 
therapy [74, 76, 98]. Our miRNA next-generation sequencing data from the LTED breast cancer 
cell lines MCF-7:5C and MCF-7:2A confirms the hypothesis that there are unique miRNA 
expression profiles in estrogen-independent vs. estrogen-dependent cells. There were 338 
miRNAs differentially expressed in the MCF-7:5C cells and 241 miRNAs differentially 
expressed in the MCF-7:2A cells when compared to the parental MCF-7 cell line. Of those 
miRNAs, 126 were differentially expressed in both of the LTED cell lines vs. MCF-7. On the 
other hand, there were also unique miRNAs that were up- or down-regulated in one of the LTED 
cell lines versus the other. 
A closer look at the miRNAs that were unique to each LTED cell line revealed an 
upregulation of specific chromosomal groups of miRNAs in MCF-7:5C (chromosome 14q32) 
and MCF-7:2A (chromosome 13q31). The miRNAs encoded on chromosome 14q32 are great in 
number, and the miRNAs we found to be upregulated in the MCF-7:5C cells represent a fraction 
of this group. Interestingly, many of the miRNAs we found upregulated in the MCF-7:5C 
chromosome 14 group, such as miR-127, miR-136, miR-411, and miR-487b, have been shown to 
be increased after estrogen deprivation (either naturally occurring or by ovariectomy) in mice 
and pigs [107, 108]. It has also been shown that the expression of miR-127 is upregulated by 
estrogen receptor-related gamma [109]. As seen in Table 4, many of these miRNAs target genes 
which are involved in cell proliferation, cell cycle, and immune response. 
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As mentioned earlier, the hormone receptor status of breast cancer cells can be predicted 
by some of these miRNAs – expression of certain chromosome 14q32 miRNAs is associated 
with ER+/PR- breast cancer [99]. This brings attention to a unique feature of the MCF-7:5C cells 
– lack of PR expression. While implications of this loss of PR are unexplored in the MCF-7:5C 
cells, there have been many studies that have tried to pinpoint the role of PR in the development 
of breast cancer. PR is important for normal breast development, especially of the mammary 
glands [110]. In studies of mice and human breast cancer cells, it seems that PR can act as an 
oncogene in vivo, and its in vitro role may be to prime breast cancer cells for growth, which is 
then sustained by action of additional proteins [111, 112]. A role for PR in breast cancer is 
further confirmed by the results from the Women’s Health Initiative in 2002 where researchers 
found a greater increase of breast cancer risk in women who took hormone replacement therapy 
that included a combination of estrogen and progestin as compared to estrogen alone [113, 114]. 
The miRNA cluster on chromosome 13q31 which includes miR-17, miR-18a, miR-19a, 
miR-20a, miR-19b, and miR-92a, is upregulated in the MCF-7:2A cells. This cluster is part of an 
incredibly intricate pathway that includes dozens of transcription factors and a series of target 
proteins involved in various cellular processes from cell proliferation and death to heart and lung 
development to immune response [115]. This miR-17/92 cluster is also known as oncomiR-1, 
and has been shown to modulate tumor formation in B-cell lymphoma [116] and enhance cell 
proliferation of medulloblastomas [117].  
Of the 126 miRNAs that were differentially expressed in both the MCF-7:5C and MCF-
7:2A cells, we chose miR-181a as our first candidate for in vitro functional analysis. We have 
shown that miR-181a is overexpressed in both MCF-7:5C and MCF-7:2A cells vs. MCF-7, and 
the Masri et al. microarray also confirms overexpression of miR-181a in MCF-7aro LTED cells 
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[74]. miR-181a was interesting to our lab in particular since we have observed a greater 
sensitivity of the MCF-7:5C cells to DNA damage and mitotic arrest induced by ionizing 
radiation and taxol treatments compared to the MCF-7 cells, and miR-181a has been shown to 
target DNA damage repair proteins such as ATM [86] and BRCA1 [94]. Expression of miR-
181a is associated with aggressive breast cancer, and inhibition of miR-181a sensitizes MDA-
MB-231 breast cancer cells to the PARP inhibitor olaparib [86]. This sensitivity to olaparib is 
due to the decreased expression of DNA repair proteins by miR-181a, and another study has 
found that upregulation of miR-181a via TGF-β signaling induces a “BRCAness” phenotype in 
the MDA-MB-231 breast cancer cell line, referring to the synthetic lethality seen in BRCA-
mutated breast cancers in response to PARP inhibition [94]. There is also evidence that AI-
resistant breast cancer cells derived from long-term letrozole-treated xenograft tumors show 
increased reliance on the alternative nonhomologous end joining DNA repair pathway and are 
responsive to PARP inhibitors [118]. In addition, expression of miR-181a was shown to enhance 
drug sensitivity in mitoxantone-resistant MCF-7 cells through its regulation of BCRP [87]. Thus, 
it was our hypothesis that MCF-7:5C and MCF-7:2A cell proliferation may be affected by loss of 
miR-181a, but more importantly that these cell lines might be more sensitive to PARP inhibition 
due to the increased expression of miR-181a in these cell lines. 
The proliferation of the MCF-7:5C cells was significantly affected by miR-181a 
knockdown at 48 and 52 hours when compared to treatment with the negative control inhibitor. 
This decrease in proliferation was not seen in the other LTED cell line MCF-7:2A, which further 
indicates the differences between these two cell lines. If these MCF-7:5C cells are relying on the 
expression of miR-181a in order to proliferate in an estrogen-deprived environment, then the 
next question is whether or not overexpression of miR-181a in estrogen-dependent MCF-7 cells 
allows them to grow in estrogen-deprived conditions. Indeed, there was an increase in the ability 
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of estrogen-deprived MCF-7 cells to proliferate and form large colonies when transfected with a 
miR-181a mimic. This indicates a potential functional relevance for miR-181a in maintaining 
estrogen-independent growth, though the mechanism by which this occurs is still unconfirmed. 
When our cells were treated with olaparib, the MCF-7 cells were more sensitive to PARP 
inhibition, though it should be noted this was just a trend and the differences weren’t significant. 
Given the overexpression of miR-181a in the LTED cells, their DNA repair proteins should be 
decreased and their sensitivity to PARP inhibition increased. Upon examining the protein 
expression of these DNA repair proteins we found that the basal expression of BRCA1 was 
highest in the MCF-7:5C cells, which may explain why it is not as sensitive to PARP inhibition 
as originally hypothesized. However, the question still remains as to why the MCF-7:5C cells are 
more sensitive to ionizing radiation and taxol, and this may be partially explained by examining 
the functionality of other DNA damage repair proteins in these cells.  
The regulation of miR-181a is achieved by action of many different factors, one of which 
includes downregulation of miR-181a expression by estrogen signaling via ERα [93]. We are 
particularly interested in the effect of ERα on miR-181a expression since our LTED cells are 
deprived of estrogen and overexpress ERα compared to the estrogen-dependent MCF-7 cells. It 
is possible that the process of deriving the MCF-7:5C and MCF-7:2A cells using long-term 
estrogen deprivation allowed for significant upregulation of miR-181a. Estrogen treatment in the 
MCF-7:5C cells did not affect miR-181a expression, likely because these cells have a different 
response to estrogen than the parental MCF-7 cells. We did, however, confirm a downregulation 
of miR-181a in estrogen-deprived MCF-7 cells (MCF-7Y) 48 hours after estrogen treatment. If 
this estrogen regulation of miR-181a involves ERα, then loss of ERα should result in restored 
expression of miR-181a. This was in fact observed upon treatment of MCF-7Y cells with a 
combination of estrogen and ICI, which degrades ERα. Likewise, in our ERα knockdown 
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experiments, use of siRNA for ERα resulted in higher expression of miR-181a in the MCF-7:5C 
cells compared to the siCtrl-transfected cells. This observation in the MCF-7:5C cells indicates 
that ligand-independent ERα is capable of suppressing miR-181a levels to some extent. 
The potential functional relevance of miR-181a in the LTED cells is encouraging, though 
not yet fully explained, and there are many miRNAs from our sequencing data that are yet to be 
explored. It will be important to pursue in vitro and in vivo analysis of miRNAs that are 
differentially expressed in both MCF-7:5C and MCF-7:2A, as well as those that were unique to 
each LTED cell line. Below, I will describe a series of experiments that would (1) fill in some 
mechanistic gaps involving miR-181a, and (2) utilize more information from the next-generation 
sequencing data to identify relevant miRNAs involved in estrogen-independent growth. While 
this list is not exhaustive, I believe it outlines the next steps relevant to the goal of this project: 
1. Filling in the mechanistic gaps involving miR-181a 
A. Confirm a role for miR-181a in estrogen-independent growth 
i. Create an MCF-7 cell line that stably overexpresses miR-181a, and compare 
growth with normal MCF-7 cells after depriving these cells of estrogen and/or 
knocking down ERα. 
ii. Using an in vivo mouse model of breast cancer, overexpress miR-181a and 
then measure sensitivity to AI treatment as compared to mice that do not 
overexpress miR-181a. 
iii. Measure levels of miR-181a in serum samples from breast cancer patients 
who are AI-resistant and compare to patients who are AI-sensitive. 
B. Determine mechanism by which miR-181a controls estrogen-independent growth 
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i. Transfect miR-181a mimic into estrogen-deprived MCF-7 cells, isolate RNA 
from these cells and MCF-7 transfected with a negative control, then conduct 
next-generation RNA sequencing to identify a global profile of genes whose 
expression is downregulated with the miR-181a mimic. 
ii. Use pathway analysis of genes altered with miR-181a mimic seen in RNA 
sequencing to identify key altered pathways, then conduct miR-181a target 
analysis – using both predicted and validated targets – for the altered genes 
seen the key pathways identified. 
iii. To confirm direct miR-181a regulation of the candidate genes identified 
above, construct a luciferase reporter containing either the 3’UTR sequence of 
the candidate genes or a mutated 3’UTR sequence to see if miR-181a directly 
binds the 3’UTR in a sequence-specific manner. 
C. Determine if miR-181a expression is directly regulated by ligand-independent ERα in 
the MCF-7:5C cells and/or ligand-dependent ERα in the MCF-7 cells 
i. Analyze the promoter sequence of the miR-181a gene for ERE sites. 
ii. If ERE sites are found in the miR-181a promoter, conduct a ChIP assay that 
immunoprecipitates ERα-bound DNA from MCF-7 and MCF-7:5C cells with 
and without estrogen, then use PCR primers specific to the miR-181a ERE 
sites to see if there is direct binding of ERα to those sites. 
2. Utilize more information from the next-generation sequencing data 
A. Explore the role of miR-30a in estrogen-independent growth.  
i. All studies of miRNAs and AI resistance, including ours, show upregulation 
of miR-30a when cells are either AI-resistant (EXE-R, Res-Let, Res-Ana) [74, 
76] or estrogen-independent (MCF-7:5C, MCF-7:2A) [57]. miR-30a has 
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recently been shown to suppress the growth, proliferation, migration, and 
invasion of breast cancer cells, which seems contrary to what we would 
expect from a miRNA that is upregulated in AI-resistant cells [119-121]. 
Thus, it would be worth conducting some preliminary functional experiments 
that could confirm how relevant miR-30a is in our estrogen-independent cells.  
B. Explore the role of the miR-17/92 cluster on chromosome 13 in MCF-7:2A cells. 
C. Explore the role of the group of miRNAs on chromosome 14 in MCF-7:5C cells. 
Experiments that have been performed in this thesis regarding miR-181a, as well as those 
described in the additional experiments above, can also be done using miR-30a and miRNAs 
from the clusters on chromosomes 13 and 14 in order to understand their role in estrogen-
independent growth. The information from these experiments may help to identify biomarker 
miRNAs that can predict the responsiveness or best alternative therapeutic option for AI-resistant 
breast tumors, or to identify novel therapeutic targets for the treatment of AI-resistant breast 
cancer. 
With the use of innovative technologies, it is now possible to use miRNAs as biomarkers 
and compile biomarker panels for diagnosis and identification of therapeutic options for cancer, 
including AI-resistant breast cancer. Circulating miRNAs are ideal for clinical use, since they are 
highly stable and can be detected by a non-invasive manner in a blood sample. Circulating 
miRNA levels in breast cancer patients have been studied at diagnosis, in early stage tumors, 
after surgical resection, following chemotherapy/radiation treatments, and following metastatic 
relapse – all to understand the unique miRNA profiles throughout the progression of breast 
cancer [122-124]. Because of the low abundance of miRNAs in the blood, the use of powerful 
detection methods such as high-throughput sequencing will need to be employed in clinical 
settings.  
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Regarding therapeutic approaches, the miRNAs overexpressed in the LTED cells could 
be eliminated via RNA interference (RNAi), while those that are underexpressed in the LTED 
cells may be part of replacement therapies. There are over 20 RNAi-based therapies employing 
various methods of siRNA delivery currently in phase I clinical trials for the treatment of 
diseases such as viral infections, hereditary disorders, and cancer [125]. The only RNA 
replacement clinical trial to date began in April of 2013 as a strategy to deliver miR-34, a tumor 
suppressive miRNA that regulates expression of BCL-2 and MYC, to patients with liver-based 
cancers [126]. Though there are no published results on this MRX34 treatment yet, a recent 
update revealed that MRX34 has a manageable safety profile with only one incident of a dose-
limiting toxicity [127]. 
Overall, we have described the miRNA profiles for two LTED breast cancer cell lines, 
and have explored the relevance of miR-181a as one functional player in the estrogen-
independent growth associated with an AI-resistant phenotype. A more complete picture of the 
differentially expressed miRNAs in endocrine-resistant breast cancer, especially AI-resistant 
breast cancer, is crucial for the development of novel biomarker signatures and therapeutic 
strategies. 
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